Brief: Sebela Pharmaceuticals Acquires Exclusive Licensing Rights To Develop And Commercialize Tegoprazan In U.S. And Canada
27/10/2022 19:54
Oct 27 (Reuters) -
* SEBELA PHARMACEUTICALS ACQUIRES EXCLUSIVE LICENSING RIGHTS TO DEVELOP AND COMMERCIALIZE
TEGOPRAZAN IN U.S. AND CANADA
* SEBELA PHARMACEUTICALS - HAS ENTERED AN EXCLUSIVE PARTNERSHIP WITH HK INNO.N CORPORATION
TO
LICENSE TEGOPRAZAN IN UNITED STATES AND CANADA
Source text for Eikon: ID:nCNW4CcGDa
Further company coverage: 195940.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HK inno.N
See all newsBrief: Hk Inno.N Corp Q3 Operating Profit 26 Billion Won, Up 0.6% From Year Earlier
Brief: Hk Inno.N Corp To Invest 97 Billion Won In New Production Facilities
Brief: Hk Inno.N Q1 Operating Profit 33.2 Billion Won, Up 31% From Year Earlier
Brief: Hk Inno.N Q3 Operating Profit 26 Billion Won, Up 16.4% From Year Earlier
Brief: Hk Inno.N Q2 Operating Profit 19.5 Billion Won, Down 20% From Year Earlier